HSP fusion protein with anti-chemorepellant agent for treatment of cancer
AssigneeThe General Hospital Corporation
InventorsMark C. Poznansky, Jeffrey A. Gelfand
Life of this patent
Estimating the term…
Abstract
This disclosure is directed to immune treatment of a disease (e.g., cancer) using a fusion protein in combination with an anti-chemorepellant agent. In particular, the fusion protein comprises an antigen-binding domain (e.g., an antibody or antibody fragment) and a stress protein domain.
Claims9
A pharmaceutical composition comprising a fusion protein and an anti-chemorepellant agent, said fusion protein comprising a cancer cell binding component and a stress protein component, wherein the fusion protein comprises the peptide sequence of SEQ ID NO:
- 2, and the cancer cell binding component is specific for an antigen expressed by breast cancer, ovarian cancer, or cervical cancer.
A kit of parts for treatment of a cancer in a patient, the kit comprising a therapeutically effective amount of an anti-chemorepellant agent and a fusion protein comprising a cancer cell binding component and a stress protein component wherein the cancer cell binding component recognizes an antigen expressed by the cancer, wherein the cancer is breast cancer, ovarian cancer, or cervical cancer, and wherein the fusion protein comprises the peptide sequence of SEQ ID NO:
- 2.
Dependencies are inferred from the claim text.